Boardroom Alpha
Start trial
8-K primary document
EYPT · Current Report (Form 8-K) · Filed December 8, 2025

Eyepoint Inc — 8-K exhibit

d60563dex32.htm
Eyepoint Inc on Boardroom Alpha
EX-3.2

Exhibit 3.2

AMENDMENT NO. 2 TO

BY-LAWS

OF

EYEPOINT PHARMACEUTICALS, INC.

THIS AMENDMENT NO. 2 TO THE BY-LAWS OF EYEPOINT PHARMACEUTICALS, INC. (this “Amendment”) is authorized, approved and adopted effective as of December 8, 2025 (the “Effective Date”).

WHEREAS, the Board of Directors (the “Board”) of EyePoint Pharmaceuticals, Inc., a Delaware corporation (the “Company”), which possesses the authority to amend the By-laws of the Company (the “By-laws”) pursuant to Section 12.1 of such By-laws and Article 8 of the Company’s Certificate of Incorporation, as amended, has authorized, approved and adopted the following Amendment to the By-laws, effective as of the Effective Date:

1. The title of the By-laws is hereby amended and restated in its entirety as follows:

“By-Laws of EyePoint, Inc.”

IN WITNESS WHEREOF, EyePoint Pharmaceuticals, Inc. has caused this Amendment to be signed by Ron Honig, the duly authorized Secretary of the Corporation, as of the date first written above.

 

By:  

/s/ Ron Honig

Name:   Ron Honig
Title:   Chief Legal Officer

[Signature Page to By-laws Amendment]

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer